A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis

Trial Profile

A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Systemic scleroderma
  • Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
  • Acronyms faSScinate
  • Sponsors Roche
  • Most Recent Events

    • 08 Nov 2017 Results of a post-hoc analysis evaluating American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (CRISS),presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 25 Oct 2017 Results of analysis evaluating Patient acceptable symptom state as an outcome measure published in the Rheumatology
    • 24 Oct 2017 Results (n=61) from the open label extension period published in the Annals of the Rheumatic Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top